BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Sistemic

Sistemic and Cynata to Collaborate on an In-process Purity Assay for Cynata’s iPSC-Derived Mesenchymal Stem Cells

May 25, 2016 By Cade Hildreth (CEO) Leave a Comment

Sistemic and Cynata Announce Cooperation on In-process Purity Assay Development for Cell Therapy (CT) Product - Depositphotos_110507274_m-2015.jpg

Sistemic Ltd. LogoBased in Glasgow, UK, Sistemic Ltd. is a company that specializes in microRNA-based services and kit-based products. Cynata Therapeutics is a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP).

Cynata’s Cymerus™ technology utilizes iPSCs originating from an adult donor as the starting material for generating mesenchymal stem cells (MSCs). The importance of this technology is that it is a process for manufacturing a consistent cell therapy product.

Cynata TherapeuticsCynata’s lead product is CYP-oo1, an iPSC-derived mesenchymal stem cell product that is anticipated to be the world’s first allogeneic iPSC product to enter a clinical trial.

In the press release below, Sistemic Ltd. and Cynata Therapeutics announce that they have entered into an agreement in which Sistemic will use its miRNA technology platforms to develop an in-process assessment assay for Cynata’s Cymerus™ cell therapy products.

MSCs are currently being explored in nearly 500 clinical trials worldwide, but technologies supporting large-scale manufacturing of MSCs are scare, which is what makes standardization and scale-up of the Cymerus technology important.

To learn more, read the full press release issued by Sistemic Ltd. below. [Read more…]

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: cell therapy, collaboration, Cymerus, cynata therapeutics, Sistemic

[ALLIANCE] Sistemic and RoosterBio Developing Regenerative Technologies Involving miRNA and Mesenchymal Stem/Stromal Cells

June 26, 2015 By Cade Hildreth (CEO) Leave a Comment

Sistemic and RoosterBio Developing Regenerative Technologies Involving miRNA and Mesenchymal Stem/Stromal Cells

Short Summary:  RoosterBio, Inc. and Sistemic have entered into an agreement to synergistically develop microRNA (miRNA)-based cell characterization technologies that will create more precise and relevant characterization panels for human mesenchymal stem cell (hMSC) products and in process cell banks.
[Read more…]

Filed Under: MSCs, Stem Cells Tagged With: hMSC, hMSC regenerative technology, human mesenchymal stem cell, microRNA, miRNA, RoosterBio, Sistemic

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.